Cargando…

Radioiodine treatment for graves’ disease: a 10-year Australian cohort study

BACKGROUND: Radioactive iodine (I(131)) is a common definitive treatment for Graves’ Disease. Potential complications include worsening, or new development of Graves’ eye disease and development of a radiation thyroiditis. The purpose of the present study was to assess outcomes of patients treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanning, Erin, Inder, Warrick J., Mackenzie, Emily
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292026/ https://www.ncbi.nlm.nih.gov/pubmed/30541519 http://dx.doi.org/10.1186/s12902-018-0322-7

Ejemplares similares

Alternating hyperthyroidism and hypothyroidism in Graves’ disease
por: Wong, Mimi, et al.
Publicado: (2018)

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
por: Fang, Ya, et al.
Publicado: (2021)

Post-radioiodine management of patients with Graves' disease
por: Collins, K, et al.
Publicado: (2012)

Radioiodine therapy and Graves’ disease – Myths and reality
por: Plazinska, Maria Teresa, et al.
Publicado: (2020)

Radioiodine Therapy of Graves' Disease and the Uptake Paradox
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020)

Should radioiodine now be first line treatment for Graves’ disease?
por: Okosieme, Onyebuchi E., et al.
Publicado: (2020)

Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid Graves’ disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2023)

Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults
por: Canto, Abigail U., et al.
Publicado: (2016)

Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves’ Disease
por: Rehman, Anis, et al.
Publicado: (2020)

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment
por: Cho, Bo Youn, et al.
Publicado: (1990)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Radioiodine therapy in patients with Graves’ disease and the effects of prior carbimazole therapy
por: Karyampudi, Arun, et al.
Publicado: (2014)

Prognostic factor analysis in 325 patients with Graves’ disease treated with radioiodine therapy
por: Yang, Danrong, et al.
Publicado: (2018)

Pattern of presentation of Graves’ disease and response to radioiodine therapy in South African men
por: Onimode, Yetunde Ajoke, et al.
Publicado: (2018)

Myopathy Associated with Acute Hypothyroidism following Radioiodine Therapy for Graves Disease in an Adolescent
por: Benavides, Valeria C., et al.
Publicado: (2010)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

Graves disease following radioiodine therapy for toxic adenoma: Clinical case report
por: Shen, Guohua, et al.
Publicado: (2017)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Extremely high doses of radioiodine required for treatment of Graves’ hyperthyroidism: a case report
por: Neto, Arnaldo Moura, et al.
Publicado: (2009)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Graves Disease Induced by Radioiodine Therapy for Toxic Nodular Goiter: A Case Report
por: Yürekli, Yakup, et al.
Publicado: (2015)

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients
por: Zhang, Ruiguo, et al.
Publicado: (2017)

A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism
por: Doi, Suhail AR, et al.
Publicado: (2001)

Acute effects of radioiodine therapy on the voice and larynx of basedow-graves patients
por: Isolan-Cury, Roberta Werlang, et al.
Publicado: (2015)

Radioiodine treatment of differentiated thyroid cancer despite history of ‘iodine allergy’
por: Puchalski, Adam R, et al.
Publicado: (2014)

SAT-417 Personalized Treatment Planning for Radioiodine Therapy of Graves’ Disease;The Collar Therapy Indicator(CoTI)
por: Santhanam, Prasanna, et al.
Publicado: (2020)

Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb
por: Jinguji, Megumi, et al.
Publicado: (2017)

Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease
por: Ito, Mitsuru, et al.
Publicado: (2019)

Weight Gain and Body Composition Changes during the Transition of Thyroid Function in Patients with Graves' Disease Undergoing Radioiodine Treatment
por: Cai, Zhenqin, et al.
Publicado: (2022)

ODP531 Worsening of pretibial myxedema following repeated doses of radioiodine treatment in a patient with hyperthyroid Graves’ disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2022)

Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer
por: Louvet, Camille, et al.
Publicado: (2016)

A Case of Violent Suicide Attempt in a Context of Myxedema Psychosis following Radioiodine Treatment in a Patient with Graves' Disease
por: Todorov, Louise, et al.
Publicado: (2019)

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation
por: Subramanian, Muthiah, et al.
Publicado: (2016)

Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease
por: Kim, Jinyoung, et al.
Publicado: (2021)

On Œdema in Graves's Disease
por: Mackenzie, Hector
Publicado: (1897)

Prognostic Value of (99m)Tc-Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy in a Cohort of Chinese Graves' Disease Patients: A Pilot Clinical Study
por: Hou, Haifeng, et al.
Publicado: (2015)

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
por: Shahida, Bushra, et al.
Publicado: (2021)

Treatment of Prolactinoma
por: Inder, Warrick J., et al.
Publicado: (2022)

Investigation and management of moderate to severe inpatient hyponatraemia in an Australian tertiary hospital
por: Berkman, Kathryn, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l64r5b44fvaunb9n362sql65le